Citius Pharmaceuticals develops critical care products including LYMPHIR, a targeted immunotherapy for relapsed or refractory cutaneous T-cell lymphoma; Mino-Lok, a catheter lock solution for catheter-related bloodstream infections; and CITI-002, a topical for hemorrhoids.